FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007175045> ?p ?o ?g. }

• W2007175045 endingPage "1045" @default.
• W2007175045 startingPage "1040" @default.
• W2007175045 abstract "No AccessJournal of UrologyAdult Urology1 Mar 2009Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has Failedis accompanied byResponse of Bladder Carcinoma Cells to TRAIL and Antisense Oligonucleotide, Bcl-2 or Clusterin TreatmentsMicroRNA-143 as a Tumor Suppressor for Bladder CancerPreventing Bladder Tumor Implantation With Photodynamic Therapy in a Rat Model Mimicking Post-Fluorescence Guided Transurethral Resection Alvaro Morales, Kiran Phadke, and Gary Steinhoff Alvaro MoralesAlvaro Morales Queen's University, Kingston, Ontario, Canada Financial interest and/or other relationship with Bioniche, Solvay and Pierre Fabre. More articles by this author , Kiran PhadkeKiran Phadke St. George Hospital, Kogarah, NSW, Australia More articles by this author , and Gary SteinhoffGary Steinhoff Vancouver Island Health Authority, Victoria, British Columbia, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2008.11.019AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the clinical efficacy and safety of mycobacterial cell wall-DNA complex after intravesical administration in patients with carcinoma in situ in whom prior therapy with bacillus Calmette-Guerin failed or in those who were treatment naïve. Materials and Methods: Patients received 6 weekly instillations of 4 or 8 mg mycobacterial cell wall-DNA complex (formulated as an emulsion) followed by 3 weekly instillations at weeks 12 and 24. Efficacy and safety were evaluated throughout the treatment phase and at months 12 and 18. Results: A total of 55 patients (mean age 74 years, 74.6% male) received 4 mg (25) or 8 mg (30) mycobacterial cell wall-DNA complex emulsion. All patients were previously treated with bacillus Calmette-Guerin except for 8 who were treatment naïve and 2 who received chemotherapy. In the intent to treat population the complete response rate was 27.3% at weeks 12 and 26 in the 4 mg group while 46.4% of patients receiving 8 mg had a complete response at both points. Mycobacterial cell wall-DNA complex was well tolerated by both dose groups. Overall 90% of all adverse events were mild to moderate in severity. Conclusions: Mycobacterial cell wall-DNA complex has shown antineoplastic activity in patients with bladder cancer with less toxicity than that associated with bacillus Calmette-Guerin administration. The tolerance and efficacy of mycobacterial cell wall-DNA complex might hold promise for the treatment of carcinoma in situ of the bladder. References 1 : Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Canc Netw2006; 4: 1027. Google Scholar 2 : The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol2001; 165: 745. Link, Google Scholar 3 : Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer2004; 91: 607. Google Scholar 4 : Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol1989; 141: 22. Link, Google Scholar 5 : Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol2003; 44: 429. Google Scholar 6 : Mycobacterium cell wall: an alternative to intravesical bacillus Calmette-Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol1996; 156: 1189. Link, Google Scholar 7 : Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol2001; 166: 1633. Link, Google Scholar 8 : Organic mercury compounds: human exposure and its relevance to public health. Toxicol Ind Health2002; 18: 109. Google Scholar 9 : Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs2001; 10: 2157. Google Scholar 10 : Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol2000; 163: 1124. Link, Google Scholar 11 : Management of BCG failures in superficial bladder cancer: a review. Eur Urol2006; 49: 790. Google Scholar 12 : Treatment options for BCG failures. World J Urol2006; 24: 481. Google Scholar 13 : Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol2000; 163: 761. Link, Google Scholar 14 : Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol2006; 24: 2729. Google Scholar 15 : Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol2006; 24: 344. Google Scholar 16 : The side effects of bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol2003; 44: 423. Google Scholar 17 : Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol2001; 40: 144. Google Scholar 18 : Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003; 169: 90. Link, Google Scholar 19 : Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol2008; 53: 992. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byNazmifar M, Williams C, Naser-Tavakolian A, Heard J, Rosser C, Theodorescu D and Ahdoot M (2022) Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin FailureJournal of Urology, VOL. 209, NO. 1, (32-48), Online publication date: 1-Jan-2023.Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J and Kamat A (2014) Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-GuérinJournal of Urology, VOL. 193, NO. 4, (1135-1143), Online publication date: 1-Apr-2015.Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, Jewett M and MacDonald G (2012) A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-GuérinJournal of Urology, VOL. 188, NO. 5, (1712-1718), Online publication date: 1-Nov-2012.Related articlesJournal of Urology20 Jan 2009Response of Bladder Carcinoma Cells to TRAIL and Antisense Oligonucleotide, Bcl-2 or Clusterin TreatmentsJournal of Urology20 Jan 2009MicroRNA-143 as a Tumor Suppressor for Bladder CancerJournal of Urology20 Jan 2009Preventing Bladder Tumor Implantation With Photodynamic Therapy in a Rat Model Mimicking Post-Fluorescence Guided Transurethral Resection Volume 181Issue 3March 2009Page: 1040-1045 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordscarcinoma in situadministrationcell wallintravesicalurinary bladder neoplasmsmycobacteriumAcknowledgmentsParticipating sites: A. Brooks, Parramatta, Australia; J. Chin, London, Canada; A. Costello, Richmond, Australia; L. Klotz and N. Fleshner, Toronto, Canada; A. Morales, Kingston, Canada; G. Neerhut, Geelong, Australia; P. Perrotte, Montreal, Canada; K. Phadke, Kogarah, Australia; P. Pommerville, Victoria, Canada; E. Ramsey and R. Bard, Winnipeg, Canada; G. Steinhoff, Victoria, Canada; P. Stricker, Darlinghurst, Australia; S. Wisniewski, Nedlans, Australia.Francois Charette, Nigel Phillips and Zvi Cohen provided critical review, and Kevin Darbyson assisted with data analysis.MetricsAuthor Information Alvaro Morales Queen's University, Kingston, Ontario, Canada Financial interest and/or other relationship with Bioniche, Solvay and Pierre Fabre. More articles by this author Kiran Phadke St. George Hospital, Kogarah, NSW, Australia More articles by this author Gary Steinhoff Vancouver Island Health Authority, Victoria, British Columbia, Canada More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2007175045 created "2016-06-24" @default.
• W2007175045 creator A5025873791 @default.
• W2007175045 creator A5037716022 @default.
• W2007175045 creator A5089135211 @default.
• W2007175045 date "2009-03-01" @default.
• W2007175045 modified "2023-10-16" @default.
• W2007175045 title "Intravesical Mycobacterial Cell Wall-DNA Complex in the Treatment of Carcinoma In Situ of the Bladder After Standard Intravesical Therapy Has Failed" @default.
• W2007175045 cites W1826410594 @default.
• W2007175045 cites W1988104298 @default.
• W2007175045 cites W2001589633 @default.
• W2007175045 cites W2018489324 @default.
• W2007175045 cites W2023543764 @default.
• W2007175045 cites W2025553797 @default.
• W2007175045 cites W2039161970 @default.
• W2007175045 cites W2047577586 @default.
• W2007175045 cites W2064504141 @default.
• W2007175045 cites W2082941803 @default.
• W2007175045 cites W2088419287 @default.
• W2007175045 cites W2111765784 @default.
• W2007175045 cites W2116250664 @default.
• W2007175045 cites W2152206210 @default.
• W2007175045 cites W2162717580 @default.
• W2007175045 cites W2168406738 @default.
• W2007175045 cites W41337129 @default.
• W2007175045 cites W4251083747 @default.
• W2007175045 cites W4295773318 @default.
• W2007175045 doi "https://doi.org/10.1016/j.juro.2008.11.019" @default.
• W2007175045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19150551" @default.
• W2007175045 hasPublicationYear "2009" @default.
• W2007175045 type Work @default.
• W2007175045 sameAs 2007175045 @default.
• W2007175045 citedByCount "56" @default.
• W2007175045 countsByYear W20071750452012 @default.
• W2007175045 countsByYear W20071750452013 @default.
• W2007175045 countsByYear W20071750452014 @default.
• W2007175045 countsByYear W20071750452015 @default.
• W2007175045 countsByYear W20071750452016 @default.
• W2007175045 countsByYear W20071750452017 @default.
• W2007175045 countsByYear W20071750452018 @default.
• W2007175045 countsByYear W20071750452019 @default.
• W2007175045 countsByYear W20071750452021 @default.
• W2007175045 countsByYear W20071750452023 @default.
• W2007175045 crossrefType "journal-article" @default.
• W2007175045 hasAuthorship W2007175045A5025873791 @default.
• W2007175045 hasAuthorship W2007175045A5037716022 @default.
• W2007175045 hasAuthorship W2007175045A5089135211 @default.
• W2007175045 hasConcept C121608353 @default.
• W2007175045 hasConcept C126322002 @default.
• W2007175045 hasConcept C126894567 @default.
• W2007175045 hasConcept C142724271 @default.
• W2007175045 hasConcept C2777546739 @default.
• W2007175045 hasConcept C2777661416 @default.
• W2007175045 hasConcept C2778065480 @default.
• W2007175045 hasConcept C2779762690 @default.
• W2007175045 hasConcept C2780352672 @default.
• W2007175045 hasConcept C71924100 @default.
• W2007175045 hasConceptScore W2007175045C121608353 @default.
• W2007175045 hasConceptScore W2007175045C126322002 @default.
• W2007175045 hasConceptScore W2007175045C126894567 @default.
• W2007175045 hasConceptScore W2007175045C142724271 @default.
• W2007175045 hasConceptScore W2007175045C2777546739 @default.
• W2007175045 hasConceptScore W2007175045C2777661416 @default.
• W2007175045 hasConceptScore W2007175045C2778065480 @default.
• W2007175045 hasConceptScore W2007175045C2779762690 @default.
• W2007175045 hasConceptScore W2007175045C2780352672 @default.
• W2007175045 hasConceptScore W2007175045C71924100 @default.
• W2007175045 hasIssue "3" @default.
• W2007175045 hasLocation W20071750451 @default.
• W2007175045 hasLocation W20071750452 @default.
• W2007175045 hasOpenAccess W2007175045 @default.
• W2007175045 hasPrimaryLocation W20071750451 @default.
• W2007175045 hasRelatedWork W1593870331 @default.
• W2007175045 hasRelatedWork W2008961876 @default.
• W2007175045 hasRelatedWork W2011206238 @default.
• W2007175045 hasRelatedWork W2012336688 @default.
• W2007175045 hasRelatedWork W2015469438 @default.
• W2007175045 hasRelatedWork W2096109977 @default.
• W2007175045 hasRelatedWork W2128075947 @default.
• W2007175045 hasRelatedWork W2142706318 @default.
• W2007175045 hasRelatedWork W4250850899 @default.
• W2007175045 hasRelatedWork W627625861 @default.
• W2007175045 hasVolume "181" @default.
• W2007175045 isParatext "false" @default.
• W2007175045 isRetracted "false" @default.
• W2007175045 magId "2007175045" @default.
• W2007175045 workType "article" @default.